|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Blood, 15 October 2005, Vol. 106, No. 8, pp. 2598-2599.
The ABCCs of myelofibrosisWEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
—Alexander Pushkin
Eugene Onegin (1823), stanza 38
Within the past 5 years, significant advances have been made in treatment of these illnesses as the diagnostic characteristics have become better defined. So far, the zenith has been reached, of course, in chronic myeloid leukemia, where not only is the disease specifically defined by cytogenetic and molecular abnormalities, but targeted chemotherapy based upon these abnormalities has resulted in spectacular therapeutic advances. A lesser degree of success has been achieved in the remaining 3 disorders, but even in these, significant advances have been made in their clinical and laboratory definition. This is especially true with the discovery of the Janus kinase 2 (JAK2) mutation, which pervades these illnesses, especially polycythemia vera, but not chronic myeloid leukemia.2 Similarly, these heretofore therapeutically resistant illnesses have likewise been responsive to new innovative therapies including, for example, interferon, imatinib,3 thalidomide,4 and bone marrow transplantation.5
Because of the lack of precision in defining response, any codified effort evaluating therapeutic effect is to be applauded. The present effort of the advisory board of the consensus conference (ABCCs) by Barosi and colleagues is a laudable beginning. It is noted that from a standpoint of writing response guidelines, they are based upon "physicians' consensus judgement," which is an expert opinion, not evidence based. The authors state that defining response is a complex issue, with which I agree. Their proposal basically offers a number of parameters that can be evaluated so that those interested in the treatment of this disease may readily communicate with each other, much like the tumor-node-metastasis (TNM) staging used in cancer. Yet, except for the changes in the bone marrow, many drugs will affect the white blood cell count (WBC), platelet count, hemoglobin, and spleen size without affecting marrow histologically or overall life-span. Thus, relatively minor changes will be considered "drug response" by these criteria. They correctly point out that monitoring changes in bone histology is not routine in either clinical practice or in clinical trials. This is true even in recent publications. Simplified and reproducible scoring systems for fibrosis are much needed. Whatever restores normal marrow histology is the sina qua non of therapy. I am impressed by the basic requirement of a "representative biopsy" defined as artifact free and at least 1.5 cm in length. This will require not only improvement in our hematopathology laboratories, but will also require tempered steel biopsy needles and a hematologist with a mighty arm. Likewise, many aspirations, even in early-stage disease, yield dry taps, making marrow cytogenetic analysis impossible. Perhaps one or another peripheral blood fluorescent in-situ hybridization (FISH) test for more common cytogenetic abnormalities can be considered.
Unlike Pushkin, who reserved his splenic remarks to 2 countries, Barosi and colleagues come from 8. This is not only a numerical achievement, but a splendid example of a multinational scientific accomplishment. They are to be congratulated.  References
  CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2005 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
